Nanomedicine News

RSS

MIT Student Develops Innovative 3D Microfluidic Platform for Cancer Therapy

MIT and Draper Laboratory have developed a device that enables drug manufacturers to develop medicines that inhibit the spread of cancer and allows them to view the migration of diseased cells.

From Massachusetts Institute of Technology 30 Jul 2011

Researchers Develop Nanotech Device Using Olfactory Receptor Proteins and Carbon Nanotubes

Scientists at the University of Pennsylvania and co-researchers from other Universities have designed a nanotech device using carbon nanotubes and olfactory receptor proteins.

28 Jul 2011

NanoViricides’ Anti-HIV Candidate Protects Human T Cells Similar to HAART Therapy

NanoViricides, a company developing special purpose nanomaterials for viral therapy, has reported in its latest animal study that its anti-HIV nanoviricide has attained anti-HIV efficiency equal to a highly active anti-retroviral therapy (HAART) triple drug cocktail.

From NanoViricides, Inc 27 Jul 2011

Alnylam, MIT Develop Core-Shell Nanoparticles for RNAi Therapeutic Delivery Applications

RNAi therapeutics firm, Alnylam Pharmaceuticals in partnership with Massachusetts Institute of Technology (MIT) has published a new paper in the Proceedings of the National Academy of Sciences on the development of core-shell nanoparticles for delivering RNAi therapeutics systemically.

27 Jul 2011

Nanotechnology May Solve the Shortcomings of Viagra

Sildenafil citrate, commonly known as Viagra, is currently the first choice drug for erectile dysfunction but despite its success oral delivery of the drug is hampered by numerous side effects, the long delay before it s...

26 Jul 2011

Safe Magnetic Nanoparticles for Detecting Breast Cancer Metastasis

MIRA researchers and their partners have received a €1.4 million grant for developing a new method to detect development of secondary tumors in breast cancer patients. The novel method uses a sophisticated highly-sensitive ‘metal detector’ and safe magnetic nanoparticles.

16 Jul 2011

Cerulean Conducts Second Phase Clinical Study of Nanopharmaceutical for Lung Cancer Patients

Cerulean Pharma, a company that specializes in development and design of nanopharmaceuticals, declared that it has administered a dose of CRLX101 to the first group of patients as part of a random, non-small cell lung cancer (NSCLC) Phase 2 clinical study.

14 Jul 2011